Stock Financial Ratios

B / Barnes Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3,442.86
Enterprise Value ($M)3,358.42
Book Value ($M)1,260.32
Book Value / Share23.08
Price / Book2.78
NCAV ($M)768.72
NCAV / Share14.08
Price / NCAV4.52
Income Statement (mra) ($M)
Net Income59.41
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio1.63
Current Ratio2.38
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.03
Return on Equity (ROE)0.05
Identifiers and Descriptors
Central Index Key (CIK)9984
Industry Groups
SIC 349 - Miscellaneous Fabricated Metal Products
Other Related CUSIPS
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding54,605,298
Weighted Average Number Of Shares Outstanding Basic54,073,407
Common Shares Outstanding53,234,401
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Assets Current Per Share0.00
Debt Per Share0.02
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share9.29
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00

Peers - Miscellaneous Fabricated Metal Products (349)

Related News Stories

Abiomed Hits New 52-Week High: 4 Factors Driving the Stock

2018-02-19 zacks
Abiomed, Inc. (ABMD - Free Report) scaled a new 52-week high of $268.72 on Feb 16, eventually closing a bit lower at $267.74. The company’s shares have gained 74.6% in the last six months, compared with the broader industry’s 14.6% gain. (59-0)

Enbridge (ENB) Beats Earnings & Revenue Estimates in Q4

2018-02-19 zacks
Enbridge Inc. (ENB - Free Report) reported strong fourth-quarter 2017 results, courtesy of higher liquid delivery volumes from the Canadian Mainline and Wood Buffalo Extension Pipeline. Higher natural gas processing volumes, lower expenses and contributions from new projects led to the encouraging numbers. Earnings per share were 48 cents, which beat the Zacks Consensus Estimate and the year-ago quarter’s figure, both of which were 42 cents. (38-0)

8 Reasons that Make Avery Dennison (AVY) a Solid Pick Now

2018-02-19 zacks
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 that are most likely to jump in price immediately. (38-0)

Soft Circulation Revenues to Hurt Gannett (GCI) Q4 Earnings

2018-02-19 zacks
Gannett Co., Inc. (GCI - Free Report) is slated to report fourth-quarter 2017 results on Feb 20. In the preceding quarter, the company delivered a positive earnings surprise of 100%. Also, its earnings surpassed the Zacks Consensus Estimate by 36.6% in the trailing four quarters. (36-0)

AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

2018-02-19 zacks
AstraZeneca (AZN - Free Report) announced that the FDA has approved a second indication for its PD-L1 inhibitor, Imfinzi. It is now approved for unresectable Stage III non-small cell lung cancer (“NSCLC”). The drug is meant for patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (74-0)

CUSIP: 067806109